FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080864067> ?p ?o ?g. }

• W2080864067 endingPage "A504" @default.
• W2080864067 startingPage "A503" @default.
• W2080864067 abstract "To evaluate and comparate the efficacy, safety and cost of the bevacizumab and ranibizumab intravitreous injections for the treatment of age related macular degeneration (AMD). A systematic review of literature was conducted. The bibliographic search covered the period between January 1996 and January 2011. The search was run on MEDLINE, EMBASE, Cochrane library, INAHTA and ECRI. The criteria employed to select the papers were: population (AMD patients), treatment (Ranibizumab or Bevacizumab), comparison (placebo or other active treatments). To assess the efficacy, it was decided to include systematic reviews and randomised clinical trials (RCT). For the safety, it was considered any type of study. The bibliographical search retrieved 731 references of articles and 51 papers were finally included: 4 were controlled clinical trials: two on Ranibizumab and two on Bevacizumab. Efficacy: Ranibizumab and Bevacizumab, as compared to placebo as to Verteporfin, gets results in terms of AMD stabilization (between 0 and 1.2% of severe visual losses as opposed to 13-16% in the control groups), in terms of reduction in the lesion size and it even achieves improvement in visual acuity in some cases. Safety: The adverse effects (of any magnitude) were more frequent in the groups treated with Ranibizumab and Bevacizumab than in the control groups (placebo and Verteporfin). The data's synthesis showed adverse effects similar in both drugs. Economic Evaluation: Drug costs for 1 year of treatment were estimated as 2.330€ for Ranibizumab and 53€ for Bevacizumab. : Both drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). Cost effectiveness analysis of bevacizumab makes this intervention highly cost effective versus ranibizumab. The price of ranibizumab would have to be drastically reduced for it to be cost effective. Public pressure may be the most potent weapon in persuading Genentech to license bevacizumab for AMD." @default.
• W2080864067 created "2016-06-24" @default.
• W2080864067 creator A5060098917 @default.
• W2080864067 creator A5074164117 @default.
• W2080864067 date "2011-11-01" @default.
• W2080864067 modified "2023-09-30" @default.
• W2080864067 title "PSS11 Ranibizumab and Bevacizumab for the Treatment of Age-related Macular Degeneration: A Systematic Review and Economic Evaluation" @default.
• W2080864067 doi "https://doi.org/10.1016/j.jval.2011.08.1476" @default.
• W2080864067 hasPublicationYear "2011" @default.
• W2080864067 type Work @default.
• W2080864067 sameAs 2080864067 @default.
• W2080864067 citedByCount "0" @default.
• W2080864067 crossrefType "journal-article" @default.
• W2080864067 hasAuthorship W2080864067A5060098917 @default.
• W2080864067 hasAuthorship W2080864067A5074164117 @default.
• W2080864067 hasBestOaLocation W20808640671 @default.
• W2080864067 hasConcept C118487528 @default.
• W2080864067 hasConcept C126322002 @default.
• W2080864067 hasConcept C141071460 @default.
• W2080864067 hasConcept C142724271 @default.
• W2080864067 hasConcept C168563851 @default.
• W2080864067 hasConcept C197934379 @default.
• W2080864067 hasConcept C204787440 @default.
• W2080864067 hasConcept C27081682 @default.
• W2080864067 hasConcept C2776403814 @default.
• W2080864067 hasConcept C2776478404 @default.
• W2080864067 hasConcept C2776694085 @default.
• W2080864067 hasConcept C2777802072 @default.
• W2080864067 hasConcept C2778257484 @default.
• W2080864067 hasConcept C2781100027 @default.
• W2080864067 hasConcept C2781148688 @default.
• W2080864067 hasConcept C2781359195 @default.
• W2080864067 hasConcept C2908647359 @default.
• W2080864067 hasConcept C535046627 @default.
• W2080864067 hasConcept C71924100 @default.
• W2080864067 hasConcept C99454951 @default.
• W2080864067 hasConceptScore W2080864067C118487528 @default.
• W2080864067 hasConceptScore W2080864067C126322002 @default.
• W2080864067 hasConceptScore W2080864067C141071460 @default.
• W2080864067 hasConceptScore W2080864067C142724271 @default.
• W2080864067 hasConceptScore W2080864067C168563851 @default.
• W2080864067 hasConceptScore W2080864067C197934379 @default.
• W2080864067 hasConceptScore W2080864067C204787440 @default.
• W2080864067 hasConceptScore W2080864067C27081682 @default.
• W2080864067 hasConceptScore W2080864067C2776403814 @default.
• W2080864067 hasConceptScore W2080864067C2776478404 @default.
• W2080864067 hasConceptScore W2080864067C2776694085 @default.
• W2080864067 hasConceptScore W2080864067C2777802072 @default.
• W2080864067 hasConceptScore W2080864067C2778257484 @default.
• W2080864067 hasConceptScore W2080864067C2781100027 @default.
• W2080864067 hasConceptScore W2080864067C2781148688 @default.
• W2080864067 hasConceptScore W2080864067C2781359195 @default.
• W2080864067 hasConceptScore W2080864067C2908647359 @default.
• W2080864067 hasConceptScore W2080864067C535046627 @default.
• W2080864067 hasConceptScore W2080864067C71924100 @default.
• W2080864067 hasConceptScore W2080864067C99454951 @default.
• W2080864067 hasIssue "7" @default.
• W2080864067 hasLocation W20808640671 @default.
• W2080864067 hasOpenAccess W2080864067 @default.
• W2080864067 hasPrimaryLocation W20808640671 @default.
• W2080864067 hasRelatedWork W1995044506 @default.
• W2080864067 hasRelatedWork W2012546470 @default.
• W2080864067 hasRelatedWork W2042956061 @default.
• W2080864067 hasRelatedWork W2079717275 @default.
• W2080864067 hasRelatedWork W2080864067 @default.
• W2080864067 hasRelatedWork W2092174330 @default.
• W2080864067 hasRelatedWork W2106441100 @default.
• W2080864067 hasRelatedWork W2143310524 @default.
• W2080864067 hasRelatedWork W2314067402 @default.
• W2080864067 hasRelatedWork W2599281049 @default.
• W2080864067 hasVolume "14" @default.
• W2080864067 isParatext "false" @default.
• W2080864067 isRetracted "false" @default.
• W2080864067 magId "2080864067" @default.
• W2080864067 workType "article" @default.